Bright Minds Biosciences, Inc. (DRUG)
20.75
+1.79
(+9.44%)
USD |
NASDAQ |
Nov 05, 16:00
20.76
+0.01
(+0.05%)
After-Hours: 20:00
Bright Minds Biosciences Shareholders Equity (Quarterly) : 216.95M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 216.95M |
| March 31, 2026 | 221.08M |
| December 31, 2025 | 65.13M |
| September 30, 2025 | 58.97M |
| June 30, 2025 | 37.98M |
| March 31, 2025 | 38.73M |
| December 31, 2024 | 40.21M |
| September 30, 2024 | 4.098M |
| June 30, 2024 | 4.457M |
| March 31, 2024 | 4.201M |
| December 31, 2023 | 4.575M |
| September 30, 2023 | 4.880M |
| Date | Value |
|---|---|
| June 30, 2023 | 5.838M |
| March 31, 2023 | 6.611M |
| December 31, 2022 | 8.094M |
| September 30, 2022 | 7.673M |
| June 30, 2022 | 6.538M |
| March 31, 2022 | 8.614M |
| December 31, 2021 | 11.84M |
| September 30, 2021 | 15.34M |
| June 30, 2021 | 17.71M |
| March 31, 2021 | 20.18M |
| December 31, 2020 | 1.639M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Amgen, Inc. | 14.35B |
| Lineage Cell Therapeutics, Inc. | 60.92M |
| Recursion Pharmaceuticals, Inc. | 905.81M |
| Agenus, Inc. | -199.08M |
| Anika Therapeutics, Inc. | 137.28M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 218.74M |
| Total Liabilities (Quarterly) | 1.793M |
| Debt to Equity Ratio | 0.0002 |
| Current Ratio | 121.98 |
| Net Debt Paydown Yield | 0.00% |